Newton, Mass. — Sep 7, 2021 — MelliCell, a biotechnology company dedicated to reversing obesity and type 2 diabetes by targeting fat cells, announced today their place on the Obesity Action Coalition’s Chairman’s Council.
The Obesity Action Coalition (OAC) helps individuals affected by the disease of obesity through education, advocacy and support. MelliCell’s platform technology (M3) allows the company to develop drug therapies that reduce the size of enlarged fat cells, thereby reversing obesity and its complications like diabetes.
“People with obesity often completely blame themselves for their weight; however, science tells us that obesity is much more complex than that. We a
re grateful that treatments for obesity continue to evolve with new and exciting therapies to help people move past the self-blame and shame,” said Joe Nadglowski, OAC President and CEO.
MelliCell is in preclinical stages of drug development as they continue to do platform validation. The OAC is the only non-profit organization whose so
le focus is helping those affected by obesity. The partnership will allow the two groups to coordinate their efforts as they move forward to create solutions for those with the disease of obesity.
“We are working to find a drug therapy that is effective and allows patients to have more valuable treatment options,” said MelliCell CEO, Prince Nnah. “Working with the OAC is key to helping us reach those affected by obesity. We are very grateful to have the OAC with us in this process.”
You can find more information on this partnership, here.
ABOUT
The Obesity Action Coalition (OAC) is a more than 75,000 member-strong 501(c)(3) National non-profit organization dedicated to giving a voice to the individual affected by the disease of obesity and helping individuals along their journey toward better health through education, advocacy and support. Our core focuses are to raise awareness and improve access to the prevention and treatment of obesity, provide evidence-based education on obesity and its treatments, fight to eliminate weight bias and discrimination, elevate the conversation of weight and its impact on health and offer a community of support for the individual affected.
MelliCell Inc. is a biotechnology company founded in 2020 to cure obesity and Type 2 diabetes. MelliCell uses proprietary technology to replicate human fat cells and test therapies for the diseases. The company is in its early funding stages and is interested in investing and partnership opportunities to further their mission to develop therapeutics that solve diabetes and obesity. If you are interested in learning more or joining their cause, please contact Prince Nnah at Prince@MelliCell.com. For media requests, please contact Michal@MelliCell.com. For more information about MelliCell’s efforts to cure diabetes and obesity, visit www.mellicell.com.
Comments